Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.
/in Hyperthermia, International Publications, Prostate Cancer /von Mark Hurwitz, Gregory T Martin, Daniel A Sidney, Charles J Welch, Jorgen L Hansen, Bruce A Bornstein, Irving D. Kaplan, H F Bowman; Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; MIT, Cambridge, MA; Hemedex, Cambridge, MA; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MAAntigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate Cancer /von T. M. Wheeler, B. Zhao, G. Sonpavde, J. D. McMannis, Y. Bai, N. Lapteva, M. Seethammagari, J. M. Levitt, D. M. Spencer, K. M. Slawin; Department of Pathology, Baylor College of Medicine, Houston, TX; University of Texas Health Science Center at Houston, Houston, TX; Texas Oncology, Baylor College of Medicine, Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Memorial Hermann Hospital-Texas Medical Center, Houston, TX; Baylor College of Medicine, Houston, TX; Vanguard Urologic Institute, Houston, TXA phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
/in Dendritic Cells, Hypernephroma, International Publications /von Fairooz F. Kabbinavar, Nazy Zomorodian, Arie S. Belldegrun, Steven G. Wong, Adrian Bot, Thinle Chodon, Begonya Comin-Anduix, Phuong Nguyen, Faraz Khan, Matthew Rettig, Allan J. Pantuck; Institute of Urologic Oncology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA; University of California, Los Angeles, Los Angeles, CA; Kite Pharma, Los Angeles, CA; Roswell Park Cancer Institute, Buffalo, NY; University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CACan Dendritic Cell Vaccination Prevent Leukemia Relapse?
/in Acute Leukemia, Dendritic Cells, International Publications /von O'Brien LJ, Guillerey C, Radford KJDendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape
/in Dendritic Cells, International Publications, NSCLC /von Mohsenzadegan M, Peng RW, Roudi RPredicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
/in Dendritic Cells, International Publications, Pancreatic Cancer /von Ito Z, Kan S, Bito T, Horiuchi S, Akasu T, Yoshida S, Kajihara M, Hokari A, Saruta M, Yoshida N, Kobayashi M, Ohkusa T, Shimodaira S, Okamoto M, Sugiyama H, Koido SThe effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
/in Cervical Cancer, Hyperthermia, International Publications /von Minnaar CA, Kotzen JA, Ayeni OA, Naidoo T, Tunmer M, Sharma V, Vangu MD, Baeyens ASafety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications /von Katherine B. Peters, Gerald E. Archer, Pamela Norberg, Weihua Xie, Stevie Threatt, Eric S Lipp, James Emmett Herndon, Patrick Healy, Kendra Congdon, Luis Sanchez-Perez, Henry S. Friedman, Annick Desjardins, Gordana Vlahovic, John H. Sampson; Duke University Medical Center, Durham, NCModulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro
/in Colorectal Cancer, Hyperthermia, International Publications /von Vancsik T, Forika G, Balogh A, Kiss E, Krenacs T
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.
- Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.
- Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).